Institute of Biomedical Research Corp. (MRES)
USD 0.01
(5.38%)
USD 0.01
(5.38%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2010 | 261.72 Thousand USD | -38.68% |
| 2009 | 426.79 Thousand USD | -89.54% |
| 2008 | 4.08 Million USD | 12127.86% |
| 2007 | 33.37 Thousand USD | -75.04% |
| 2006 | 133.75 Thousand USD | 0.0% |
| 2004 | 14.33 Thousand USD | 29.14% |
| 2003 | 11.1 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2010 Q2 | 52.22 Million USD | 45085.52% |
| 2010 Q3 | 35.95 Thousand USD | -99.93% |
| 2010 Q4 | 18.11 Thousand USD | -49.62% |
| 2010 Q1 | 115.57 Thousand USD | 17.46% |
| 2010 FY | 261.72 Thousand USD | -38.68% |
| 2009 Q2 | 29.23 Thousand USD | -80.29% |
| 2009 FY | 426.79 Thousand USD | -89.54% |
| 2009 Q3 | 18.51 Thousand USD | -36.67% |
| 2009 Q1 | 148.31 Thousand USD | 73.91% |
| 2009 Q4 | 98.39 Thousand USD | 431.42% |
| 2008 Q1 | 3.45 Million USD | 1879.32% |
| 2008 Q4 | 85.28 Thousand USD | -5.31% |
| 2008 Q3 | 90.06 Thousand USD | -12.68% |
| 2008 Q2 | 103.14 Thousand USD | -97.02% |
| 2008 FY | 4.08 Million USD | 12127.86% |
| 2007 Q2 | 147.68 Thousand USD | 1213.56% |
| 2007 FY | 33.37 Thousand USD | -75.04% |
| 2007 Q4 | 174.72 Thousand USD | -41.44% |
| 2007 Q3 | 298.37 Thousand USD | 102.04% |
| 2007 Q1 | 11.24 Thousand USD | 176.17% |
| 2006 FY | 133.75 Thousand USD | 0.0% |
| 2006 Q4 | 4071.00 USD | -72.72% |
| 2006 Q3 | 14.92 Thousand USD | 281.59% |
| 2006 Q2 | 3911.00 USD | 132.12% |
| 2006 Q1 | -12.17 Thousand USD | -291.67% |
| 2005 Q3 | 136.82 Thousand USD | 2248.96% |
| 2005 Q4 | 6353.00 USD | -95.36% |
| 2005 Q2 | 5825.00 USD | 381.8% |
| 2005 Q1 | 1209.00 USD | -32.31% |
| 2004 Q3 | 1042.00 USD | -85.5% |
| 2004 Q2 | 7188.00 USD | 91.99% |
| 2004 FY | 14.33 Thousand USD | 29.14% |
| 2004 Q4 | 1786.00 USD | 71.4% |
| 2004 Q1 | 3744.00 USD | 0.0% |
| 2003 FY | 11.1 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 80.401% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 94.809% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 99.114% |
| Nascent Biotech, Inc. | 2.22 Million USD | 88.263% |
| Rebus Holdings, Inc. | 664 Thousand USD | 60.583% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 99.297% |
| Qrons Inc. | 643.67 Thousand USD | 59.339% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | 32.816% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 99.544% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | 37.006% |
| Skye Bioscience, Inc. | 13.54 Million USD | 98.068% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.698% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 94.678% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.694% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 91.025% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 82.574% |
| Mesoblast Limited | 5.9 Million USD | 95.565% |
| Marizyme, Inc. | 19.23 Million USD | 98.64% |
| Genus plc | 147.7 Million USD | 99.823% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 97.019% |
| Pharming Group N.V. | 225.49 Million USD | 99.884% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 87.225% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 80.491% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 96.861% |
| ContraFect Corporation | 56.88 Million USD | 99.54% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 94.063% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 82.301% |
| IMV Inc. | 37.7 Million USD | 99.306% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 90.62% |
| MultiCell Technologies, Inc. | 567.42 USD | -46025.621% |
| ONE Bio Corp. | 6.44 Million USD | 95.938% |
| Accustem Sciences Inc. | 3.74 Million USD | 93.014% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.695% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | 50.8% |
| Q BioMed Inc. | 3.43 Million USD | 92.384% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 98.941% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 90.039% |
| Biomind Labs Inc. | 994.18 Thousand USD | 73.674% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.737% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 85.126% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 96.104% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 85.962% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 1146.904% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 98.365% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 85.738% |
| GB Sciences, Inc. | 1.42 Million USD | 81.575% |
| Alpha Cognition Inc. | 9.7 Million USD | 97.303% |
| HST Global, Inc. | 140.9 Thousand USD | -85.744% |
| CSL Limited | 3.44 Billion USD | 99.992% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 76.734% |
| Halberd Corporation | 74.84 Thousand USD | -249.705% |
| Enzolytics Inc. | 2.17 Million USD | 87.992% |
| Agentix Corp. | 1.37 Million USD | 80.92% |
| Resverlogix Corp. | 12.71 Million USD | 97.941% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 92.831% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.983% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 74.93% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 89.117% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 83.428% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 92.313% |
| AVAX Technologies, Inc. | 7.31 Million USD | 96.42% |
| Zenith Capital Corp. | 8.94 Million USD | 97.073% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.968% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -1402.359% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 89.34% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -52.602% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 86.375% |
| Kadimastem Ltd | 2.41 Million USD | 89.141% |
| Helix BioMedix, Inc. | 1.97 Million USD | 86.728% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 97.592% |
| BioStem Technologies, Inc. | 22.97 Million USD | 98.861% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -44.214% |
| LadRx Corporation | 3.81 Million USD | 93.134% |
| Cell Source, Inc. | 4.32 Million USD | 93.949% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 71.66% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 71.66% |
| NovAccess Global Inc. | 2.46 Million USD | 89.39% |
| Affymax, Inc. | 39.38 Million USD | 99.335% |
| Itoco Inc. | 919.14 Thousand USD | 71.525% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 93.825% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 76.611% |
| Mobile Lads Corp. | 554.54 Thousand USD | 52.804% |
| CytoDyn Inc. | 18.05 Million USD | 98.551% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -939.874% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -18.924% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 81.566% |
| SYBLEU INC | 160.87 Thousand USD | -62.688% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 85.59% |
| International Stem Cell Corporation | 5.27 Million USD | 95.035% |
| Bioxytran, Inc. | 3.82 Million USD | 93.149% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -397.181% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -1186.565% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 99.278% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 83.824% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 64.431% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 91.587% |
| Neutra Corp. | 243.82 Thousand USD | -7.344% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 98.501% |
| PureTech Health plc | 144.59 Million USD | 99.819% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 98.723% |
| IXICO plc | 4.7 Million USD | 94.44% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 97.025% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.778% |
| CSL Limited | 3.89 Billion USD | 99.993% |
| Cellectis S.A. | 97.32 Million USD | 99.731% |